EYPT - ピ―シビダ (EyePoint Pharmaceuticals Inc.) ピ―シビダ

 EYPTのチャート


 EYPTの企業情報

symbol EYPT
会社名 EyePoint Pharmaceuticals Inc (ピ―シビダ)
分野(sector) Capital Goods   資本財(工業製品)
産業(industry) Biotechnology: Laboratory Analytical Instruments  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 アイポイント・ファーマシューティカルズ(Eyepoint Pharmaceuticals Inc.)(旧名:pSivida Corp.)は主に慢性眼疾患の治療用の薬物送達製品を開発する。同社は目の裏目の病気の治療のための3つの製品を開発した。後部セグメントブドウ膜炎のためのMedidurは、主要な第III相臨床試験にあるリード製品候補である。糖尿病性黄斑浮腫(DME)のILUVIENは、米国および欧州連合(EU)諸国で販売されている主要ライセンス製品である。また、Retisertを含む。Medidurは、眼の後部に影響を与える慢性非感染性ブドウ膜炎(後部ブドウ膜炎)を治療するように設計される。ILUVIENは、単回注射からDMEの治療を提供する注射可能なマイクロインサートである。Retisertは、後区域ブドウ膜炎の治療を提供するインプラントである。同社の製品開発プログラムは、DurasertとTethadurの2つの技術プラットフォームを利用して、慢性疾患治療薬と生物製剤を提供することに重点を置く。   ピ―シビダは、米国の医薬品会社。目の奥の慢性疾患の治療に焦点を当てた医薬品「Durasert」と「Tethadur」を開発。また、製品候補「Medidur」は、第3相臨床試験段階である。同社の主要製品「ILUVIEN」は、欧州連合(EU)で承認され、米国食品医薬品局(FDA)では承認が保留されている。   
本社所在地 480 Pleasant Street Watertown MA 02472 USA
代表者氏名 Goran A. Ando ゴラン・アンドド
代表者役職名 Chairman of the Board 取締役会会長
電話番号 +1 617-926-5000
設立年月日 31868
市場名 NASDAQ National Market System
ipoyear ―年
従業員数 44人
url www.eyepointpharma.com
nasdaq_url https://www.nasdaq.com/symbol/eypt
adr_tso
EBITDA EBITDA(百万ドル) -25.12600
終値(lastsale) 3.28
時価総額(marketcap) 244399517.44
時価総額 時価総額(百万ドル) 250.36050
売上高 売上高(百万ドル) 2.96100
企業価値(EV) 企業価値(EV)(百万ドル) 228.89350
当期純利益 当期純利益(百万ドル) -53.17100
決算概要 決算概要 BRIEF: For the fiscal year ended 30 June 2018 Eyepoint Pharmaceuticals Inc revenues decreased 61% to $3M. Net loss increased from $18.5M to $53.2M. Revenues reflect United States segment decrease of 62% to $2.9M. Higher net loss reflects Research and Development Expense increase of 12% to $14.9M (expense) General and administrative increase of 3% to $10.1M (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -$0.52 to -$1.15.

 EYPTのテクニカル分析


 EYPTのニュース

   EyePoint Pharmaceuticals Announces $16.5 Million Monetization of ILUVIEN® Royalty with SWK Holdings Corporation  2020/12/18 12:00:00 GlobeNewswire
WATERTOWN, Mass., Dec. 18, 2020 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and…
   Eyepoint Pharmaceuticals (NASDAQ:EYPT) Cut to Hold at Zacks Investment Research  2020/10/24 08:34:42 Dakota Financial News
Zacks Investment Research cut shares of Eyepoint Pharmaceuticals (NASDAQ:EYPT) from a buy rating to a hold rating in a research report released on Wednesday morning, Zacks.com reports. According to Zacks, “EyePoint Pharmaceuticals Inc. operates as a biopharmaceutical company. It engaged in the development of drug devices to treat debilitating diseases of the eye disorders and […]
   Investment Analysts’ Weekly Ratings Updates for Eyepoint Pharmaceuticals (EYPT)  2020/10/23 15:26:41 The Olympia Report
A number of firms have modified their ratings and price targets on shares of Eyepoint Pharmaceuticals (NASDAQ: EYPT) recently: 10/21/2020 – Eyepoint Pharmaceuticals was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “EyePoint Pharmaceuticals Inc. operates as a biopharmaceutical company. It engaged in the development […]
   Eyepoint Pharmaceuticals (NASDAQ:EYPT) Upgraded to “Buy” at Zacks Investment Research  2020/10/23 06:18:45 Transcript Daily
Zacks Investment Research upgraded shares of Eyepoint Pharmaceuticals (NASDAQ:EYPT) from a hold rating to a buy rating in a report released on Monday, Zacks.com reports. The firm currently has $0.50 price objective on the stock. According to Zacks, “EyePoint Pharmaceuticals Inc. operates as a biopharmaceutical company. It engaged in the development of drug devices to […]
   Eyepoint Pharmaceuticals (NASDAQ:EYPT) Stock Rating Lowered by Zacks Investment Research  2020/10/23 01:18:42 Dispatch Tribunal
Eyepoint Pharmaceuticals (NASDAQ:EYPT) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued to investors on Wednesday, Zacks.com reports. According to Zacks, “EyePoint Pharmaceuticals Inc. operates as a biopharmaceutical company. It engaged in the development of drug devices to treat debilitating diseases of the eye disorders […]
   EyePoint Pharmaceuticals Announces $16.5 Million Monetization of ILUVIEN® Royalty with SWK Holdings Corporation  2020/12/18 12:00:00 GlobeNewswire
WATERTOWN, Mass., Dec. 18, 2020 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and…
   Eyepoint Pharmaceuticals (NASDAQ:EYPT) Cut to Hold at Zacks Investment Research  2020/10/24 08:34:42 Dakota Financial News
Zacks Investment Research cut shares of Eyepoint Pharmaceuticals (NASDAQ:EYPT) from a buy rating to a hold rating in a research report released on Wednesday morning, Zacks.com reports. According to Zacks, “EyePoint Pharmaceuticals Inc. operates as a biopharmaceutical company. It engaged in the development of drug devices to treat debilitating diseases of the eye disorders and […]
   Investment Analysts’ Weekly Ratings Updates for Eyepoint Pharmaceuticals (EYPT)  2020/10/23 15:26:41 The Olympia Report
A number of firms have modified their ratings and price targets on shares of Eyepoint Pharmaceuticals (NASDAQ: EYPT) recently: 10/21/2020 – Eyepoint Pharmaceuticals was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “EyePoint Pharmaceuticals Inc. operates as a biopharmaceutical company. It engaged in the development […]
   Eyepoint Pharmaceuticals (NASDAQ:EYPT) Upgraded to “Buy” at Zacks Investment Research  2020/10/23 06:18:45 Transcript Daily
Zacks Investment Research upgraded shares of Eyepoint Pharmaceuticals (NASDAQ:EYPT) from a hold rating to a buy rating in a report released on Monday, Zacks.com reports. The firm currently has $0.50 price objective on the stock. According to Zacks, “EyePoint Pharmaceuticals Inc. operates as a biopharmaceutical company. It engaged in the development of drug devices to […]
   Eyepoint Pharmaceuticals (NASDAQ:EYPT) Stock Rating Lowered by Zacks Investment Research  2020/10/23 01:18:42 Dispatch Tribunal
Eyepoint Pharmaceuticals (NASDAQ:EYPT) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued to investors on Wednesday, Zacks.com reports. According to Zacks, “EyePoint Pharmaceuticals Inc. operates as a biopharmaceutical company. It engaged in the development of drug devices to treat debilitating diseases of the eye disorders […]
   EyePoint Pharmaceuticals Announces $16.5 Million Monetization of ILUVIEN® Royalty with SWK Holdings Corporation  2020/12/18 12:00:00 GlobeNewswire
WATERTOWN, Mass., Dec. 18, 2020 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and…
   Eyepoint Pharmaceuticals (NASDAQ:EYPT) Cut to Hold at Zacks Investment Research  2020/10/24 08:34:42 Dakota Financial News
Zacks Investment Research cut shares of Eyepoint Pharmaceuticals (NASDAQ:EYPT) from a buy rating to a hold rating in a research report released on Wednesday morning, Zacks.com reports. According to Zacks, “EyePoint Pharmaceuticals Inc. operates as a biopharmaceutical company. It engaged in the development of drug devices to treat debilitating diseases of the eye disorders and […]
   Investment Analysts’ Weekly Ratings Updates for Eyepoint Pharmaceuticals (EYPT)  2020/10/23 15:26:41 The Olympia Report
A number of firms have modified their ratings and price targets on shares of Eyepoint Pharmaceuticals (NASDAQ: EYPT) recently: 10/21/2020 – Eyepoint Pharmaceuticals was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “EyePoint Pharmaceuticals Inc. operates as a biopharmaceutical company. It engaged in the development […]
   Eyepoint Pharmaceuticals (NASDAQ:EYPT) Upgraded to “Buy” at Zacks Investment Research  2020/10/23 06:18:45 Transcript Daily
Zacks Investment Research upgraded shares of Eyepoint Pharmaceuticals (NASDAQ:EYPT) from a hold rating to a buy rating in a report released on Monday, Zacks.com reports. The firm currently has $0.50 price objective on the stock. According to Zacks, “EyePoint Pharmaceuticals Inc. operates as a biopharmaceutical company. It engaged in the development of drug devices to […]
   Eyepoint Pharmaceuticals (NASDAQ:EYPT) Stock Rating Lowered by Zacks Investment Research  2020/10/23 01:18:42 Dispatch Tribunal
Eyepoint Pharmaceuticals (NASDAQ:EYPT) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued to investors on Wednesday, Zacks.com reports. According to Zacks, “EyePoint Pharmaceuticals Inc. operates as a biopharmaceutical company. It engaged in the development of drug devices to treat debilitating diseases of the eye disorders […]

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 ピ―シビダ EYPT EyePoint Pharmaceuticals Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)